Drug Trial Radar · NCT06283459
Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2
Last checked: Nov 19, 2026Latest source record: Jul 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Jun 4, 2024
Primary completion
Mar 7, 2025
Study completion Mar 7, 2025
Sponsor
- Lead sponsor
- ImunonIndustry
- Sponsor type
- Industry
- First posted
- Feb 28, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is an open-label phase 1/2, dose-escalation study. Participants will receive a single intramuscular (IM) dose of IMNN-101 on Day 0 in the deltoid muscle and will be followed through 12 months post-vaccination (through Study Day 365).
Conditions
- SARS CoV 2 Infection
Interventions
IMNN-101Biological
IMNN-101 is a DNA vaccine encoding SARS-CoV-2 Omicron XBB.1.5 spike antigen. The drug product is a suspension of the DNA plasmid formulated with the facilitating agent, bis-(aza-18-crown-6)-poloxamer (Crown poloxamer, CP), and adjuvant AlPO4.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with local and systemic reactogenicity adverse events and all adverse eventsTime frame: 1 month
- Number of participants with geometric mean titer (GMT) of the serum neutralizing antibody (Nab) against the Omicron XBB.1.5 strain.Time frame: 12 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Beth Israel Deaconess Medical Center
Boston, Massachusetts
DM Clinical Research
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.